We investigated the utility of a 10-min 13C-urea breath test (13C-UBT) using 100mg of 13C-urea; this is a simple and rapid method for the detection of Helicobacter pylori infection. One hundred and fifty-one patients in whom the identification of H. pylori was established by rapid urease test, culture, and histology of six biopsy specimens underwent 254 13C-UBT examinations before and/or after eradication treatment. In the 133 patients who did not receive eradication treatment, the calculated sensitivity of the 10-min 13C-UBT was 99.4% and specificity 100% when the cut-off point was set at 3.5/1000, using a mass spectrometer. In the 121 patients who received eradication treatment, this cut-off point gave a sensitivity of 86.7%, a specificity of 99.1%, and a positive predictive value of 92.9%, with a negative predictive value of 98.1%. There were no significant differences between the diagnosis of H. pylori infection at 1 month and more than 3 months after the endpoint of eradication treatment. The 10-min 13C-UBT is suitable for the diagnosis of H. pylori infection before and after eradication treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

eradication treatment
20
pylori infection
16
13c-urea breath
8
breath test
8
helicobacter pylori
8
10-min 13c-ubt
8
cut-off point
8
diagnosis pylori
8
pylori
5
eradication
5

Similar Publications

Doxorubicin, a widely used anthracycline antibiotic, has been a cornerstone in cancer chemotherapy since the 1960s. In addition to doxorubicin, anthracycline chemotherapy medications include daunorubicin, idarubicin, and epirubicin. For many years, doxorubicin has been the chemotherapy drug of choice for treating a broad variety of cancers.

View Article and Find Full Text PDF

Introduction: Lotilaner ophthalmic solution (0.25%) is the first United States Food and Drug Administration (US FDA)-approved drug for treating Demodex blepharitis. In pivotal trials, it was found to be well tolerated and demonstrated a significant reduction in collarettes and mite density after a 6-week treatment regimen.

View Article and Find Full Text PDF

Visceral leishmaniasis (VL) is a vector-borne disease caused by the obligate intracellular protozoan in India. VL can be complicated by post-kala-azar dermal leishmaniasis (PKDL), a macular or nodular rash that develops in 10%-20% of patients after treatment of VL in India. Patients with PKDL are infectious to sand flies, promoting further transmission of the parasite.

View Article and Find Full Text PDF

Unlabelled: is an acid-fast, aerobic, non-motile, and biofilm-forming bacterium. The increasing prevalence of mycobacterial infections makes it necessary to find new methods to combat the resistance of bacteria to conventional antibiotics. is an emerging pathogen that is intrinsically drug resistant due to several factors, including an impermeable cell envelope, drug efflux pumps, target-modifying enzymes, and the ability to form thick, robust biofilms.

View Article and Find Full Text PDF

Evaluating stakeholder coordination and partnerships for NTD elimination in Taraba state, Nigeria: a multi-level analysis.

BMC Infect Dis

January 2025

Pan-African Community Initiative on Education and Health (PACIEH), Ekulu West GRA, No. 8 Somto Anugwom Close, Enugu, Enugu State, 400102, Nigeria.

Introduction: Nigeria has a significant burden of NTDs with more than 120 million people at risk of the dominant NTDs namely Lymphatic Filariasis, Onchocerciasis, and Schistosomiasis. Control efforts have involved the four levels of governance with programs focused on vector control, preventive chemotherapy, water, sanitation and health education. However, the coordination across these levels and with multiple stakeholders remains unclear especially in states like Taraba that have received significant funding from local non-governmental organisations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!